Intrinsic dissolution as a tool for evaluating drug solubility in accordance with the biopharmaceutics classification system

Dissolution Technologies

Volumn 18, Issue 3, 2011, Pages 6-13

  Issa, Michele G ^a   Ferraz, Humberto G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG PENETRATION; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; INTRINSIC DISSOLUTION TEST; PH;

EID: 80052709171     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT180311P6     Document Type: Article

References (45)

1. Zhu, H.; Zhou, H.; Seitz, K. Bioavailability and Bioequivalence. In Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice; Qiu, Y., Chen, Y., Zhang, G. G. Z., Liu, L., Porter, W. R., Eds.; Academic Press: Burlington, MA, 2009; pp 341-364.
2. Dokoumetzidis, A.; Macheras, P. A century of dissolution research: From Noyes and Whitney to the biopharmaceutics classification system. Int. J. Pharm.2006, 321, 1-11.
3. Panchagnula, R.; Thomas, N. S. Biopharmaceutics and pharmacokinetics in drug research. Int. J. Pharm. 2000, 201, 131-150.
4. Pelkonen, O.; Boobis, A. R.; Gundert-Remy, U. In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. Eur. J. Clin. Pharmacol. 2001, 57 (9), 621-629.
5. Lindenberg, M.; Kopp, S.; Dressman, J. B. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 2004, 58, 265-278.
6. Varma, M. V. S.; Khandavilli, S.; Ashokraj, Y.; Jain, A.; Dhanikula, A.; Sood, A.; Thomas, N. S.; Pillai, O.; Sharma, P.; Gandhi, R.; Agrawal, S.; Nair, V.; Panchagnula, R. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. Curr. Drug Metab. 2004, 5, 375-388.
7. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drugclassification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res.1995, 12 (3), 413-420.
8. Lennernäs, H.; Abrahamsson, B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol. 2005, 57, 273-285.
9. Lipka, E.; Amidon, G. L. Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J. Controlled Release 1999, 62, 41-49.
10. Löbenberg, R.; Amidon, G. L. Modern biovailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000, 50, 3-12.
11. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, Guidance for Industry; U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U. S. Government Printing Office: Washington, DC, 2000.
12. Rao, V. M.; Sanghvi, R.; Zhu, H. Solubility of Pharmaceutical Solids. In Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice; Qiu, Y., Chen, Y., Zhang, G. G. Z., Liu, L., Porter, W. R., Eds.; Academic Press: Burlington, MA, 2009; pp 3-23.
13. Steele, G. Preformulation Predictions from Small Amounts of Compound as an Aid to Candidate Drug Selection. In Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form; Gibson, M., Ed.; Interpharm/CRC: Boca Raton, FL, 2001; pp 21-88.
14. Baka, E.; Comer, J. E.; Takács-Novák, K. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J. Pharm. Biomed. Anal. 2008, 46 (2), 335-341.
15. Yu, L. X.; Carlin, A. S.; Amidon, G. L.; Hussain A. S. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int. J. Pharm. 2004, 270 (1-2), 221-227.
16. Sehic, S.; Betz, G.; Hadzidedic, S.; El-Arini, S. K.; Leuenberger, H. Investigation of intrinsic dissolution behavior of different carbamazepine samples. Int. J. Pharm. 2010, 386 (1-2), 77-90.
17. The United States Pharmacopeia and National Formulary USP 32-NF 27; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2009.
18. Yu, L. X.; Amidon, G. L.; Polli, J. E.; Zhao, H.; Mehta, M. U.; Conner, D. P.; Shah, V. P.; Lesko, L. J.; Chen, M.; Lee, V. H. L.; Hussain, A. S. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm. Res. 2002, 19 (7), 921-925.
19. Zakeri-Milani, P.; Barzegar-Jalali, M.; Azimi, M.; Valizadeh, H. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur. J. Pharm. Biopharm. 2009, 73 (1), 102-106.
20. Ku, M. S. Use of the Biopharmaceutical Classification System in Early Drug Development. AAPS J. 2008, 10 (1), 208-212.
21. Karalis, V.; Macheras, P.; Van Peer, A.; Shah, V. P. Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability. Pharm. Res. 2008, 25 (8), 1956-1962.
22. Martinez, M. N.; Amidon, G. L. A Mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J. Clin. Pharmacol. 2002, 42 (6), 620-643.
23. Ashford, M. Assessment of Biopharmaceutical Properties. In Pharmaceutics: The Science of Dosage Form Design; Aulton, M. E., Ed.; Churchill Livingstone: London, 2002; pp 253-274.
24. Jung, S. J.; Choi, S. O.; Um, S. Y.; Kim, J. I.; Choo, H. Y. P.; Choi, S. Y.; Chung, S. Y. Prediction of the permeability of drugs through study on quantitative structure- permeability relationship. J. Pharm. Biomed. Anal.2006, 41 (2), 469-475.
25. Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediaterelease, solid oral dosage forms. WHO technical Report series No. 937; World Health Organization: Geneva, 2006; pp 391-415.
26. Dokoumetzidis, A.; Valsami, G.; Macheras, P. Modelling and simulation in drug absorption processes. Xenobiotica 2007, 37 (10-11), 1052-1065.
27. Yazdanian, M.; Briggs, K.; Jankovsky, C.; Hawi, A. The"high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm. Res. 2004, 21 (2), 293-299.
28. Benet, L. Z.; Amidon, G. L.; Barends, D. M.; Lennernäs, H.; Polli, J. E.; Shah, V. P.; Stavchansky, S. A.; Yu, L. X. The use of BDDCS in classifying the permeability of marketed drugs. Pharm. Res. 2008, 25 (3), 483-488.
29. Papadopoulou, V.; Valsami, G.; Dokoumetzidis, A.; Macheras, P. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCD-MD): Theoretical basis and practical examples. Int. J. Pharm. 2008, 361 (1-2), 70-77.
30. Skinner, M.; Kanfer, I. Intrinsic dissolution rate and solubility studies on josamycin, a macrolide antibiotic. Int. J. Pharm. 1992, 88 (1-3), 151-158.
31. Ayres, C.; Burke, W.; Dickinson, P; Kirk, G.; Pugh R.; Sharma- Singh, G.; Kittlety, R. Intrinsic dissolution rate determinations in early development and relevance to in vivo performance. Am. Pharm. Rev. 2007, 10 (1), 74-78.
32. Viegas, T. X.; Curatella, R. U.; Winkle, L. L. V.; Brinker, G., Measurement of Intrinsic Drug Dissolution Rates Using Two Types of Apparatus. Pharm. Technol. 2001, 25 (6), 44-53.
33. Lehto, P.; Aaltonen, J.; Niemelä, P.; Rantanen, J.; Hirvonen, J.; Tanninen, V. P.; Peltonen, L. Simultaneousmeasurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices. Int. J. Pharm. 2008, 363 (1-2), 66-72.
34. Azarmi, S.; Roa, W.; Löbenberg, R. Current perspectives in dissolution testing of conventional and novel dosage forms. Int. J. Pharm. 2007, 328 (1), 12-21.
35. European Pharmacopoeia, 6th ed.; European Directorate for the Quality of Medicines, Council of Europe: Strasbourg, France, 2008.
36. Peltonen, L.; Liljeroth, P.; Heikkilä, T.; Kontturi, K.; Hirvonen, J. Dissolution testing of acetylsalicylic acid by a channel flow method-correlation to USP basket and intrinsic dissolution methods. Eur. J. Pharm. Sci.2003, 19, 395-401.
37. Bartolomei, M.; Bertocchi, P.; Antoniella, E; Rodomonte, A. Physico-chemical characterisation and intrinsic dissolution studies of a new hydrate form of diclofenac sodium: comparison with anhydrous form. J. Pharm. Biomed. Anal. 2006, 40 (5), 1105-1113.
38. Kim, M.; Jin, S.; Kim, J.; Park, H. J.; Song, H.; Neubert, R. H. H., Hwang, S. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 2008, 69 (2), 454-465.
39. Agrawal, S.; Ashokraj, Y.; Bharatam, P.; Pillai, O.; Panchagnula, R. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur. J. Pharm. Sci. 2004, 22 (2-3), 127-144.
40. Wang, J.; Flanagan, D. R. Fundamentals of Dissolution. In Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice; Yihong, Q., Chen, Y., Zhang, G. Z. Z., Liu, L., Porter, W., Eds.; Academic Press: Burlington, MA, 2009; pp 309-316.
41. The British Pharmacopoeia, The Stationary Office: London, 2009; pp A310-A311.
42. Berge, C. M.; Tsinman, O.; Voloboy, D.; Lipp, D.; Stones, S.; Avdeef, A. Miniaturized Intrinsic Dissolution Rate (Mini-IDRTM) Measurement of Griseofulvin and Carbamazepine. Dissolution Technol. 2007, 14 (4), 39-41.
43. Tsinman, K.; Avdeef, A.; Tsinman, O.; Voloboy, D. Powder Dissolution Method for Estimating Rotating Disk Intrinsic Dissolution Rates of Low Solubility Drugs. Pharm. Res. 2009, 26 (9), 2093-2100.
44. Carstensen, J. T. Dissolution from Particles and Surfaces. In Advanced Pharmaceutical Solids; Drugs and the Pharmaceutical Sciences, Vol. 110; Marcel Dekker, Inc.: New York, 2001; pp 191-194.
45. Yu, L. X.; Carlin A. S.; Hussain, A. S. Feasibility Studies of Intrinsic Dissolution Rate as an Alternative Method to Determine BCS Solubility Membership. Presented at American Association of Pharmaceutical Sciences annual meeting, 2000.